Advance Online
Two women standing up in an open car, looking and smiling at the camera behind them.
Advance Online

FDA Approves ZORYVE™ Cream for Adolescents and Adults

A new non-steroidal topical medication option for plaque and inverse psoriasis.

On July 29, 2022, the U.S. Food and Drug Administration (FDA) approved ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas (where skin makes contact with other skin), in patients 12 years of age or older. A topical phosphodiesterase-4 (PDE4) inhibitor, ZORYVE is the first and only FDA-approved non-steroidal topical in its class. [1]

The approval is based on comprehensive results from the pivotal DERMIS-1 and DERMIS-2 Phase 3 studies. ZORYVE improved the severity and impact of itch, as early as Week 2. In both studies, ZORYVE improved overall signs and symptoms of psoriasis at Weeks 4 and 8 compared to vehicle. ZORYVE is approved for once-daily treatment with no limitations on duration of use. Of individuals who continued treatment with ZORYVE for at least 52 weeks in an open-label long-term safety trial, 45% evaluated as “Clear” or “Almost Clear” at Week 52 (IGA = 0 or 1). [1]

ZORYVE is the only topical for which efficacy has been specifically demonstrated in the treatment of intertriginous (or inverse) psoriasis. [1] Inverse psoriasis is found in the armpits, groin, under the breasts, and in other skin folds on the body.


Learn more about your treatment options for psoriatic disease, including non-steroidal topicals.

Explore treatments

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.